Fig. 2: EPZ-6438 long term treatment improves anti-CD38 therapeutic antibodies efficacy in MM cells. | Leukemia

Fig. 2: EPZ-6438 long term treatment improves anti-CD38 therapeutic antibodies efficacy in MM cells.

From: EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma

Fig. 2

A 1 µM EPZ-6438 increases CD38 cell surface expression in 4 HMCLs at days 3, 6, and 9 (n = 3). B 9 days of 1 µM EPZ-6438 treatment improves ADCC induced by Daratumumab (Dara 1 µg/ml) and Isatuximab (Isa 1 µg/ml) in XG-20 CD38low MM cell line (Paired Student T-test, *p < 0.05; **p < 0.01). NK numbers represent the different blood samples from healthy donors used for NK cell isolation. C 12 days of EPZ-6438 treatment induces significant CD38 protein re-expression in primary MM samples (n = 5, p < 0.05 using paired Student T-test) (i). 12 days of 1 µM EPZ-6438 treatment improves MM cell lysis induced by 48 h of Daratumumab (Dara 1 µg/ml) treatment in eight primary MM bone marrow samples, including four collected at relapse after Daratumumab treatment (ii).

Back to article page